Evidence map›Paper›PMID 42610621›Full record

ArticleMolecular biology and evolution2026

Identification and masking of artifactual and misleading within-host variants in deep-sequencing SARS-CoV-2 data.

Klara Marie Anker, Rosario Evans Pena, Steven A Kemp, Joseph Clarke, Lele Zhao, David Bonsall, Nicholas Grayson, Matthew Bashton, Ann Sarah Walker, Tanya Golubchik and 3 more

Abstract read
In one paragraph

Article in Molecular biology and evolution, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Klara Marie AnkerPandemic Sciences Institute, University of Oxford, Oxford, UK.ORCID 0000-0002-2459-8583
Rosario Evans PenaPandemic Sciences Institute, University of Oxford, Oxford, UK.ORCID 0000-0001-5777-8049
Steven A KempPandemic Sciences Institute, University of Oxford, Oxford, UK.ORCID 0000-0001-7077-6793
Joseph ClarkeBig Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0009-0002-2466-9932
Lele ZhaoPandemic Sciences Institute, University of Oxford, Oxford, UK.ORCID 0000-0002-2807-1914
David BonsallPandemic Sciences Institute, University of Oxford, Oxford, UK.ORCID 0000-0003-2187-0550
Nicholas GraysonPandemic Sciences Institute, University of Oxford, Oxford, UK.ORCID 0000-0002-9998-6783
Matthew BashtonHub for Biotechnology in the Built Environment, Northumbria University, Newcastle-Upon-Tyne, UK.ORCID 0000-0002-6847-1525
Ann Sarah WalkerNuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-0412-8509
Tanya GolubchikBig Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0003-2765-9828
Matthew HallPandemic Sciences Institute, University of Oxford, Oxford, UK.ORCID 0000-0002-2671-3864
Katrina LythgoePandemic Sciences Institute, University of Oxford, Oxford, UK.ORCID 0000-0002-7089-7680
COVID-19 Genomics UK (COG-UK) Consortium

Funding

Department of Health and Social CareGenome Research LimitedHealth Protection Research Unit NIHR207397Li Ka Shing FoundationMedical Research CouncilNational Institute of Health Research MC_PC_19027NHSNorthern Ireland GovernmentOxford EPSRC Centre EP/S02428X/1Oxford NIHR Biomedical Research CentreResearch EnglandRoyal SocietyScottish GovernmentUK Health Security AgencyUKHSAUniversity of OxfordWellcome Sanger InstituteWellcome TrustWellcome Trust 107652/Z/15/ZWellcome Trust 203141/Z/16/ZWellcome Trust 227438/Z/23/ZWelsh Government
6 · The paper itself

Abstract

Deep-sequencing data are increasingly used to study within-host viral diversity and to inform evolutionary inference. For SARS-CoV-2, analyses based on intra-host single-nucleotide variants (iSNVs) have been widely applied to quantify within-host diversity and infer transmission dynamics. However, these applications critically depend on the reliable identification of low-frequency variants, which remain vulnerable to systematic and technical artifacts. In this study, we show that recurrent artifactual iSNVs are common in large-scale SARS-CoV-2 sequencing data and can persist even under conservative minor allele frequency thresholds. Using data from the UK's Office for National Statistics COVID-19 Infection Survey, we demonstrate that such artifacts are predominantly sequencing center-specific rather than primer-specific. Each center exhibits a modest, distinct set of recurrent artifactual variants showing little overlap with sites routinely masked at the consensus level. To address this, we developed a systematic, dataset-aware framework that uses recurrence within sequencing datasets to identify small, noise-adapted sets of artifactual iSNVs to mask. Applying this framework reduces spurious sharing of low-frequency variants between samples and qualitatively alters downstream inferences, including estimates of within-host diversity and transmission bottleneck sizes. Although this study focused on SARS-CoV-2, it is likely that recurrent artifactual iSNVs will be problematic for other viruses as mass-sequencing becomes increasingly routine. Together, these findings highlight the importance of explicit, dataset-aware artifact control for robust inference from within-host variation, particularly as genomic studies increasingly seek to exploit sub-consensus diversity in rapidly evolving pathogens.

Indexed as

COVID-19High-Throughput Nucleotide SequencingSARS-CoV-2ArtifactsGene FrequencyGenetic VariationGenome, ViralHumansPolymorphism, Single Nucleotideintrahost variantsSARS-CoV-2sequencing artifactstransmission bottleneckvariant maskingviral evolution

Identifiers

PMID42610621
PMCPMC13533334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.